Abstract: A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity.

Abstract: A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity.

Abstract: Described are methods of treatment of a small cell lung cancer subject expressing Schlafen-11 (SLFN 11) with a Poly (ADP-ribose) polymerases (PARP) inhibitor or a pharmaceutically acceptable salt thereof. Specifically, the method comprising detecting SLFN 11 in a tumor cell sample from the subject, and administering effective amount of a PARP inhibitor, such as talazoparib or the tosylate salt of talazoparib, to the subject.

Abstract: Provided are methods for determining whether a vaccinated animal is uninfected or infected with a virulent wild-type virus. Methods, vaccines and viruses are disclosed that are useful to seratologically distinguish infected from uninfected animals in populations of animals vaccinated with a properly incapacitated virus lacking an antigen of the wild-type virus.

Abstract: The present invention provides recombinant DNA molecules comprising a sequence encoding a pseudorabies virus (PRV) glycoprotein selected from the group consisting of gI, gp50, and gp63, host cells transformed by said recombinant DNA molecule sequences, the gI, gp50 and gp63 polypeptides. The present invention also provides subunit vaccines for PRV, methods for protecting animals against PRV infection and methods for distinguishing between infected and vaccinated animals.

Abstract: Methods for isolating thymidine kinase-encoding DNA of a herpes virus are described. These methods utilize degenerate primers based on regions of relatively conserved amino acid sequence in herpes virus thymidine kinase proteins to initiate a polymerase chain reaction which yields large amounts of the thymidine kinase-encoding DNA. The methods are illustrated in the isolation of the thymidine kinase gene of feline herpes virus, which can be used to construct recombinant thymidine kinase-negative feline herpes viruses for purposes of constructing live vaccines and expression vectors. In addition, the regulatory elements of the feline herpes virus thymidine kinase gene are useful in the construction of recombinant DNA vectors.

Abstract: Provided are methods for determining whether a vaccinated animal is uninfected or infected with a virulent wild-type virus. Methods, vaccines and viruses are disclosed that are useful to seratologically distinguish infected from uninfected animals in populations of animals vaccinated with a properly incapacitated virus lacking an antigen of the wild-type virus.

Abstract: Provided are a virus vaccine, comprising a properly incapacitated virus lacking an antigen of the wild-type virus which is useful for serologically distinguished between vaccinated and infected animals, methods for distinguishing between vaccinated and infected animals and multivalent vaccines.

Abstract: The present invention relates to the use of the polyadenylation signal from the gene for bovine growth hormone to achieve a high level of expression of peptides in eukaryotic cells. Accordingly, the present invention provides a recombinant DNA compound comprising: a first nucleotide sequence which contains a promoter capable of initiating transcription of a gene; a second nucleotide sequence which encodes a gene for a polypeptide other than bovine growth hormone, including genomic and other intron containing forms thereof; a third nucleotide sequence which contains a bovine growth hormone polyadenylation signal; and a fourth nucleotide sequence which optionally contains a selectable marker. The first, second and third sequences are operably linked in sequence to form a functional genetic unit capable of being expressed. The fourth sequence, which is optionally provided, is useful for determining whether or not the DNA of the present invention has been incorporated into a living cell.

Abstract: The present invention provides a recombinant DNA sequence encoding the pseudorabies virus (PRV) glycoprotein gX, host cells transformed by said DNA sequence, the gX polypeptide, and methods and kits for detecting animals infected with PRV.

Abstract: The present invention provides a recombinant DNA sequence encoding the pseudorabies virus (PRV) glycoprotein gX, host cells transformed by said DNA sequence, the gX polypeptide, and methods and kits for detecting animals infected with PRV.

Abstract: Provided are a virus vaccine, comprising a properly incapacitated virus lacking an antigen of the wild-type virus which is useful for serologically distinguishing between vaccinated and infected animals, methods for distinguishing between vaccinated and infected animals and multivalent vaccines.

Abstract: Specific DNA sequence insertions, deletions and substitutions (i.e., combinations of sequence deletion and insertion) in eukaryotic cell or viral genomes are stably effected through use of selectable DNA sequences comprising a herpesvirus thymidine kinase (tk) gene.